Browse by author
Lookup NU author(s): Professor Alan Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Seventeen patients with malignant mesothelioma were treated in a phase II study with carboplatin, a cisplatin analogue without significant nephrotoxicity or neurotoxicity. The drug was given in a dose of 300-400 mg/m2 by i.v. infusion, repeating at 28-day intervals. One patient achieved a complete clinical and radiological remission of 15 months' duration, and a second patient achieved a partial response of 11 months' duration (overall response rate 12%; overall response rate in previously untreated patients 20%). Four other previously untreated patients achieved symptomatic relief. Treatment was well tolerated without severe side-effects. Carboplatin, like most other cytotoxic drugs, is active only in a small minority of patients with mesothelioma, but its ability to achieve occasional good responses and frequent symptomatic relief, combined with low toxicity, may justify a short therapeutic trial in patients whose tumour is symptomatic.
Author(s): Mbidde EK, Harland SJ, Calvert AH, Smith IE
Publication type: Article
Publication status: Published
Journal: Cancer Chemotherapy and Pharmacology
Year: 1986
Volume: 18
Issue: 3
Pages: 284-285
Print publication date: 01/12/1986
ISSN (print): 0344-5704
ISSN (electronic): 1432-0843
URL: http://dx.doi.org/10.1007/BF00273404
DOI: 10.1007/BF00273404
PubMed id: 3542270
Altmetrics provided by Altmetric
